- Home
- NOTV vs YMAT Comparison
NOTV vs YMAT Comparison
Compare NOTV & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- YMAT
- Stock Information
- Founded
- NOTV 1974
- YMAT 1970
- Country
- NOTV United States
- YMAT Taiwan
- Employees
- NOTV N/A
- YMAT N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- YMAT Recreational Games/Products/Toys
- Sector
- NOTV Health Care
- YMAT Consumer Discretionary
- Exchange
- NOTV Nasdaq
- YMAT Nasdaq
- Market Cap
- NOTV 57.7M
- YMAT 76.4M
- IPO Year
- NOTV 1997
- YMAT 2025
- Fundamental
- Price
- NOTV $1.69
- YMAT $1.55
- Analyst Decision
- NOTV Strong Buy
- YMAT
- Analyst Count
- NOTV 1
- YMAT 0
- Target Price
- NOTV $5.00
- YMAT N/A
- AVG Volume (30 Days)
- NOTV 429.6K
- YMAT 836.4K
- Earning Date
- NOTV 08-06-2025
- YMAT 01-01-0001
- Dividend Yield
- NOTV N/A
- YMAT N/A
- EPS Growth
- NOTV N/A
- YMAT N/A
- EPS
- NOTV N/A
- YMAT 0.07
- Revenue
- NOTV $505,299,000.00
- YMAT $17,563,985.00
- Revenue This Year
- NOTV $5.64
- YMAT N/A
- Revenue Next Year
- NOTV $5.16
- YMAT N/A
- P/E Ratio
- NOTV N/A
- YMAT $22.13
- Revenue Growth
- NOTV 0.85
- YMAT N/A
- 52 Week Low
- NOTV $1.15
- YMAT $1.50
- 52 Week High
- NOTV $6.48
- YMAT $6.45
- Technical
- Relative Strength Index (RSI)
- NOTV 41.79
- YMAT N/A
- Support Level
- NOTV $1.65
- YMAT N/A
- Resistance Level
- NOTV $1.85
- YMAT N/A
- Average True Range (ATR)
- NOTV 0.13
- YMAT 0.00
- MACD
- NOTV -0.01
- YMAT 0.00
- Stochastic Oscillator
- NOTV 8.33
- YMAT 0.00
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.